Dendritic Cell News and Research

Latest Dendritic Cell News and Research

IL-36 might be a useful therapeutic target in treatment of psoriasis

Psoriasis is a chronic inflammatory skin disorder that affects approximately 2% of the world's population. A group of inflammatory molecules known as interleukins activate an immune response that causes itchy skin, but it is unclear how the skin cells and immune cells communicate.

16 Oct 2012

Autoimmune disease myasthenia gravis halted in mice

Working with mice, Johns Hopkins researchers say they have developed a gene-based therapy to stop the rodent equivalent of the autoimmune disease myasthenia gravis by specifically targeting the destructive immune response the disorder triggers in the body.

1 Oct 2012

Researchers identify how p110delta molecule controls the body's inflammatory responses

Researchers at Queen Mary, University of London have discovered how a key molecule controls the body's inflammatory responses. The molecule, known as p110delta, fine-tunes inflammation to avoid excessive reactions that can damage the organism.

1 Oct 2012

Neuronal inhibition plays key role in memory formation

Stefan Remy and colleagues at the German Center for Neurodegenerative Diseases (DZNE) and the University of Bonn have illuminated how this system works. "The system acts like a filter, only letting the most important impulses pass," explains Remy. "This produces the targeted neuronal patterns that are indispensible for long-term memory storage."

7 Sep 2012

ImmunoCellular completes enrollment in ICT-107 Phase II trial for glioblastoma

ImmunoCellular Therapeutics, Ltd. announced today that the company has completed enrollment for its Phase II randomized, double-blinded, placebo-controlled, multi-center trial of its dendritic cell-based cancer vaccine ICT-107 for treatment of glioblastoma.

6 Sep 2012

Gene therapy approach restores ability to smell in mouse model of congenital anosmia

Scientists funded by the National Institutes of Health have restored the ability to smell in a mouse model of a human genetic disorder that causes congenital anosmia-the inability to smell from birth. The approach uses gene therapy to regrow cilia, cell structures that are essential for olfactory function.

3 Sep 2012

Scientists restore sense of smell in mice through gene therapy

Scientists have restored the sense of smell in mice through gene therapy for the first time -- a hopeful sign for people who can't smell anything from birth or lose it due to disease.

3 Sep 2012

Study explains why some cancer vaccines are not as effective as hoped

A research report published in the September 2012 issue of the Journal of Leukocyte Biology offers a possible explanation of why some cancer vaccines are not as effective as hoped, while at the same time identifies a new therapeutic strategy for treating autoimmune problems. In the report, scientists suggest that cancer, even in the very early stages, produces a negative immune response from dendritic cells, which prevent lymphocytes from working against the disease.

31 Aug 2012

NW Bio receives MHRA approval to initiate DCVax-L Phase III GBM brain cancer trial in the U.K.

Northwest Biotherapeutics announced today that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom, for the Company's 300-patient Phase III clinical trial of DCVax-L immune therapy for Glioblastoma multiforme brain cancer (GBM) to proceed in the U.K.

24 Aug 2012

New results describe development of DC cancer vaccine with enhanced immunogenic potential

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at Radboud University Nijmegen Medical Centre in the Netherlands announced today that they have published new pre-clinical results in the journal Cancer Immunology Immunotherapy describing the development of a dendritic cell (DC) cancer vaccine with enhanced immunogenic potential.

23 Aug 2012

Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor

An experimental immune-based therapy more than doubled median survival of patients diagnosed with the most aggressive malignant brain tumor, Cedars-Sinai Medical Center researchers reported in Cancer Immunology, Immunotherapy, published online Aug. 3.

16 Aug 2012

Data from IMUC’s ICT-107 Phase I trial on glioblastoma multiforme accepted for publication

ImmunoCellular Therapeutics announced today that clinical data from its Phase I trial of ICT-107 was accepted for publication, and is currently in the online edition of the prestigious medical journal Cancer Immunology, Immunotherapy.

9 Aug 2012

Promising implications for improving cellular immunotherapy for treatment of cancer

New research from the Trudeau Institute laboratory of Dr. Edward L. Pearce (Washington University) has promising implications for improving a treatment for cancer known as cellular immunotherapy. The findings were just published in the The Journal of Immunology.

30 Jul 2012

Researchers describe new human tissue dendritic cell with cross-presenting function

Researchers in Newcastle and Singapore have identified a new type of white blood cell which activates a killing immune response to an external source - providing a new potential target for vaccines for conditions such as cancer or Hepatitis B.

30 Jul 2012

HIV drug resistance: an interview with Dr. Silvia Bertagnolio

Sexual intercourse is the major mode of HIV transmission. HIV may also be transmitted through sharing of needles or contaminated blood products (although this is rare).

27 Jul 2012

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.

26 Jul 2012

ImmunoCellular receives Japanese patent allowance for brain cancer technology

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of a Japanese patent relating to a technology for the treatment of brain cancer for which the Company holds an exclusive, worldwide license.

10 Jul 2012

Does alcohol kill brain cells?

Several origins have been suggested for the idea that alcohol kills brain cells. Some link it to the temperance movement, which called for prohibition of alcohol.

9 Jul 2012

ImmunoCellular to expand ICT-107 Phase IIb trial on GBM

ImmunoCellular Therapeutics, Ltd., a clinical stage biotechnology company that is focused on developing new immune-based products to treat cancer, announced today that it will expand its current Phase IIb trial of ICT-107 from 102 to up to 123 patients with glioblastoma multiforme (GBM) and who are HLA-A1/A2 positive.

2 Jul 2012

Researchers identify primary player of the biochemical bugle call

Researchers have identified the primary player of the biochemical bugle call that musters the body's defenders against viral infection.

14 Jun 2012

Dendritic Cell News and Research

Latest Dendritic Cell News and Research

IL-36 might be a useful therapeutic target in treatment of psoriasis

Autoimmune disease myasthenia gravis halted in mice

Researchers identify how p110delta molecule controls the body's inflammatory responses

Neuronal inhibition plays key role in memory formation

ImmunoCellular completes enrollment in ICT-107 Phase II trial for glioblastoma

Gene therapy approach restores ability to smell in mouse model of congenital anosmia

Scientists restore sense of smell in mice through gene therapy

Study explains why some cancer vaccines are not as effective as hoped

NW Bio receives MHRA approval to initiate DCVax-L Phase III GBM brain cancer trial in the U.K.

New results describe development of DC cancer vaccine with enhanced immunogenic potential

Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor

Data from IMUC’s ICT-107 Phase I trial on glioblastoma multiforme accepted for publication

Promising implications for improving cellular immunotherapy for treatment of cancer

Researchers describe new human tissue dendritic cell with cross-presenting function

HIV drug resistance: an interview with Dr. Silvia Bertagnolio

ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme

ImmunoCellular receives Japanese patent allowance for brain cancer technology

Does alcohol kill brain cells?

ImmunoCellular to expand ICT-107 Phase IIb trial on GBM

Researchers identify primary player of the biochemical bugle call

Immunology eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Dendritic Cell News and Research

Latest Dendritic Cell News and Research

Immunology eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in